

November 4-6 2026 | Boston, MA

www.adc-payload.com

SAVE \$900 BY
REGISTERING BEFORE
FRIDAY, AUGUST 7

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

3rd Annual

adc

Payload Summit

Harnessing the Power of ADC Payloads

Diversifying ADC Payloads as Warheads
for Overcoming Tumor Resistance,
with Optimized Efficacy, Potency, &
Differentiated Mechanisms of Action

Expert Speakers Include:



Kashif Khan
Director, Medicinal
Chemistry &
Oncology
AstraZeneca



Prajna Behera
Senior Principal
Scientist, Oncology
Innovation
GSK



Alyson Smith
Executive Director,
Biology
Callio Therapeutics



Paul Song
Chief Scientific
Officer
Genequantum
Healthcare



Krzysztof Brzozka
Chief Scientific
Officer
RYVU Therapeutics



Tara Arvedson
Chief Scientific
Officer
Hexagon Bio

Proud to Partner With:



+1 617 455 4188 @ adc@hansonwade.com

www.adc-payload.com Antibody Drug Conjugates World ADC Event Series



Redefining ADC Payload Design to Overcome Resistance & Improve Outcomes

3rd Annual
adc
Payload Summit
November 4-6 2026
Boston, MA

The 3rd ADC Payload Summit is the industry's dedicated forum for scientists driving the next generation of ADC payload innovation.

Bringing together leaders across **payload discovery, medicinal chemistry, biology, translational science, toxicology**, and **ADC development**, this summit is designed to help you tackle the critical challenges shaping payload selection and clinical success today. From overcoming resistance and improving therapeutic index to advancing novel mechanisms and dual-payload strategies, the agenda delivers practical insights from the teams pushing payload innovation forward.

Join 70+ payload pioneers from **AstraZeneca, GSK, AbbVie, Takeda, Hexagon Bio, Callio Therapeutics, GeneQuantum** and more to gain exclusive lessons learned from emerging payload programs, evaluate new modalities including molecular glues and NMT inhibitors, and explore strategies for translating differentiated payloads into clinical success.

Featuring a new **Curated Matchmaking Roundtable** experience alongside highly interactive discussions, workshops, and networking opportunities, this year's summit provides more opportunities than ever to connect with potential collaborators, **benchmark your approach against peers**, and **discover the partnerships needed to accelerate next-generation ADC development**.

Whether you're advancing established payload classes or pioneering entirely new mechanisms, this is your opportunity to connect with the scientists redefining the future of ADC payload innovation.

What Our Speakers Have to Say

“I really enjoyed and appreciated the level of openness of the presentations and commentary - that facilitated critical thought and learning, especially with such a multidisciplinary audience”

**Senior Investigator,
Research, Biohaven**

“The conference, particularly the workshops, was very interactive. In addition, most speakers are leading experts in the field”

**Professor & Faculty
Fellow, Northeastern
University**

What's New for 2026?



Dual Payload ADCs From Concept to Clinical Advantage

Discover how developers such as **Hexagon** and **GeneQuantum Healthcare** are engineering dual and multi-payload ADCs to combine synergistic mechanisms, overcome resistance, and unlock broader therapeutic potential. Explore the chemistry, biology, and translational considerations shaping the next generation of multi-payload therapeutics.



Rethinking the Limits of Classical Payloads

Challenge conventional assumptions around payload innovation by examining how antibody design, linker optimization, tumor biology, and immune-mediated mechanisms can enhance the performance of established payload classes. Learn with experts from **Takeda** and **Medicovestor** when optimization is enough, and when an entirely new approach is needed.



Curated Matchmaking Roundtables

Move beyond traditional networking with **interactive, challenge-focused discussion groups** designed to connect you with peers tackling similar scientific and development hurdles. Exchange insights, identify potential collaborators, and discover practical solutions to ADC payload challenges.



Defining the Future Payload Landscape

Join a forward-looking discussion including **AstraZeneca, GSK, Callio Therapeutics** and **Corellia AI** on how resistance mechanisms, tumor heterogeneity, and evolving biology will shape the next generation of ADC payload strategies. Gain perspective on the payload classes, partnership models, and portfolio decisions that will determine future success in the ADC field.

Your Expert Speakers

adc
Payload Summit
November 4-6 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Alyson Smith
Executive Director, Biology
Callio Therapeutics



Andrew Phillips
Senior Director
AbbVie



Dori Thomas-Karyat
Chief Executive Officer
Synthis Therapeutics



James Prudent
Chief Executive Officer
Centrose LLC



Kakajan Komurov
Chief Scientific and
Technology Officer
Corellia AI



Kashif Khan
Director, Medicinal
Chemistry & Oncology
AstraZeneca




Koichi Ito
Senior Director, Biology
Prelude Therapeutics



Krzysztof Brzozka
Chief Scientific Officer
RYVU Therapeutics



Michael Weickert
Chief Executive Officer
Pacylex Pharmaceuticals



Patrick Strout
Senior Scientist
AstraZeneca



Paul Song
Chief Scientific Officer
**Genequantum
Healthcare**



Prajna Behera
Senior Principal Scientist,
Oncology Innovation
GSK



Robert Lutz
Chief Scientific Officer
Iksuda Therapeutics



Satyajit Mitra
Executive Director, Head
of Oncology
Akari Therapeutics



Seah Lim
Chief Executive Officer
Medicovestor



Tara Arvedson
Chief Scientific Officer
Hexagon Bio



Vicky Appleman
Director, Oncology Drug
Discovery
Takeda



Wanping Geng
Vice President
CanWell Pharma

Knowledgeable presenters and ADC research focused topics
about emerging ADC payload development

Associate Director, Product Quality, Sm & Antibodies, **BioNTech**

Pre-Conference Workshop Day

Wednesday, November 4, 2026



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Check-in, Coffee & Light Breakfast

8.00

Workshop A

9.00

Engineering Dual Payload ADCs to Expand Therapeutic Window, Overcome Resistance & Unlock Novel Synergies

This workshop examines the emerging complexity of dual- and multi-payload ADC design, where the promise of enhanced efficacy through mechanistic synergy must be balanced against fundamental constraints in biology, chemistry, and translational predictability. It asks whether combining payloads truly expands the therapeutic window or whether it introduces new layers of variability in exposure, toxicity, and resistance evolution.

- Explore how dual and multi payload ADCs are enabling synergistic mechanisms that outperform traditional combination approaches
- Understand how rational payload pairing strategies can expand addressable patient populations and overcome emerging resistance mechanisms
- Examine the chemistry and translational challenges associated with linker payload synthesis, *in vivo* evaluation, and optimization of dual payload systems
- Learn how developers are integrating novel payload classes alongside established cytotoxics to revive promising mechanisms and differentiate next generation ADCs
- Assess evolving clinical and preclinical data supporting dual payload approaches and identify where the field is seeing meaningful therapeutic advantage

Workshop Leaders



Tara Arvedson
Chief Scientific Officer
Hexagon Bio

Lunch Break & Networking

12.00

Workshop B

1.00

Expanding the ADC Therapeutic Window to Improve Safety, Efficacy, & Clinical Success

This workshop examines one of the central tensions in ADC development, asking how potent is too potent. It explores whether increasing payload potency truly expands the therapeutic window or simply shifts toxicity into new and sometimes less predictable profiles. Through case based discussion, the session will analyze how DAR optimization, site specific conjugation, linker selection and payload characteristics collectively shape safety, efficacy and clinical usability

- Examine how payload permeability, linker stability and intracellular release location collectively determine safety margins and clinical feasibility
- Challenge the assumption that extreme payload potency is always required for ADC success, tracing where this paradigm originated and when it no longer holds
- Discuss trade-offs between payload potency, off-target toxicity, dosing flexibility, and clinical tolerability
- Explore practical strategies to balance potency, dosing flexibility and tolerability including mechanism selective payload design and refined conjugation approaches to improve therapeutic index

Workshop Leaders



Andrew Phillips
Senior Director
AbbVie

End of Pre-Conference Workshop Day

4.00



+1 617 455 4188

@ adc@hansonwade.com

www.adc-payload.com

Antibody Drug Conjugates

World ADC Event Series



Conference Day One

Thursday, November 5, 2026



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Check In, Coffee & Light Breakfast

8.55 Chair's Opening Remarks

Engineering the Next Era of ADCs Through Payload Innovation

9.00 Defining the Next Era of ADC Payload Revolution From Proven Mechanisms to Transformative Innovation



Robert Lutz
Chief Scientific Officer
Iksuda Therapeutics

- Examine why continued reliance on tubulin and topoisomerase payloads is becoming strategically and clinically unsustainable, as hundreds of ADCs with the same mechanisms move into the clinic and patient populations become saturated and resistant
- Provide a reality-based assessment of which novel payload classes are genuinely close to clinical readiness, separating mechanisms with real translational momentum from those that remain conceptual
- Argue why the ADC field is at an inflection point, where measured rule-breaking and early risk-taking on novel payloads is now required to avoid long-term stagnation

9.30 Developing a Novel Cytotoxic & Immunogenic Payload Class for the Next Generation of ADCs



Krzysztof Brzozka
Chief Scientific Officer
RYVU Therapeutics

- Examine the rationale for payloads that induce immunogenic cell death (ICD) rather than relying on conventional cytotoxic mechanisms alone
- Compare the activity of Ryvu's lead payload candidates against established ADC payloads across multiple tumor targets and models
- Understand how novel payload mechanisms can expand therapeutic opportunities, improve differentiation, and address emerging resistance in the ADC landscape



10.00 Speed Networking & Refreshments

A structured opportunity for face-to-face discussions and exchange of business cards across the ADC payload community, enabling focused exchange on the latest advances in payload design, resistance mechanisms, linker strategies, and translational challenges shaping clinical success.

Unlocking New Biology-Driven ADC Payload Mechanisms Independent of Cytotoxicity

11.00 Unlocking Oncogenic Pathway Inhibition as a New Class of ADC Payloads Beyond Classical Cytotoxic Mechanisms



Kakajan Komurov
Chief Scientific and
Technology Officer
Corellia AI

- Examine the scientific rationale for leveraging oncogenic pathway inhibition as an ADC payload strategy, demonstrating how targeted delivery of PI3K/mTOR inhibitors can achieve meaningful anti-tumor activity beyond traditional cytotoxic mechanisms
- Explore preclinical data supporting ADC-enabled delivery of Omipalisib to overcome the systemic toxicities that have historically limited PI3K/mTOR inhibitors, unlocking a previously inaccessible therapeutic window in pathway-addicted tumors
- Define the critical biological and engineering considerations required to optimize non-cytotoxic payloads, including linker-spacer design, conjugation strategy, and the unique pharmacology created by ADC-mediated pathway inhibition



11.30 Session reserved for WuXi XDC

Conference Day One

Thursday, November 5, 2026



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

12.00 Unlocking NMT Inhibitors as a Novel ADC Payload Class Beyond Conventional Cytotoxic Mechanisms



Michael Weickert
Chief Executive Officer
Pacylex Pharmaceuticals

- Review new clinical and mechanistic data from the most advanced NMT inhibitor, zelenistat, and examine how emerging efficacy, safety, and biological activity findings are helping validate NMT inhibition as a promising ADC payload mechanism
- Explore the biology underpinning NMT inhibition, including emerging understanding of isozyme dependency in cancer cells and why NMT1 represents an attractive and potentially selective therapeutic vulnerability
- Assess why growing biological, clinical, and translational evidence is increasing interest in NMT inhibitors as ADC payloads, and discuss how the mechanism could be deployed to address resistance and enable greater payload differentiation beyond conventional cytotoxic approaches



12.30 Lunch & Networking Break

De-risking ADC Development Through Improved Clinical Translation & Predictive Preclinical Modelling

1.30 From Design to Discontinuation: A DNA-Targeting ADC Payload Case Study in Translational Tolerability Challenges



Patrick Strout
Senior Scientist
AstraZeneca

- End-to-end case study of a DNA-targeting ADC program, from payload selection and antibody pairing through to *in vitro* and *in vivo* evaluation
- Exploration of key chemistry and biology challenges, including conjugation strategy, assay predictivity, and species-dependent translational gaps
- Deep dive into tolerability outcomes in higher-order species and the critical learnings that shaped program termination and future redesign strategies

2.00 Roundtable Discussion: Enhancing Payload Selection & Clinical Translation Through Human-Relevant Models to Increase Predictive Confidence



- Collaborate with peers to identify why promising ADC payloads frequently fail in clinical development, exploring the translational challenges associated with efficacy, toxicity, exposure, and resistance
- Discuss how organoids, tissue-on-chip platforms, microfluidic systems, and other human-relevant models can improve payload selection and uncover safety liabilities earlier in development
- Exchange lessons learned and practical solutions for building more predictive preclinical strategies, before sharing key recommendations with the wider audience to help improve ADC development success rates



2.30 Afternoon Break & Poster Session

An interactive platform for scientists, drug developers, and industry experts to showcase the latest advances in ADC payload innovation, enabling attendees to engage directly with presenters across areas including novel payload discovery, biology-driven mechanisms of action, linker-payload design, translational evaluation, resistance biology, and next-generation ADC strategies.

Conference Day One

Thursday, November 5, 2026



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Translating Payload Biology & Clinical Lessons From Established Payloads into Next-Generation ADC Design

3.30 Panel Discussion: Maximize the Value of Classical Payloads Through Smarter Design & Better Development Decisions

- Assess whether the performance ceiling of established payloads is driven by the payload itself or by broader ADC design factors, including antibody biology, internalization dynamics, and target selection
- Explore the impact of tumor biology and cell-cycle kinetics on ADC efficacy, discussing whether reliance on traditional cytotoxic mechanisms leaves significant tumor populations untreated and how developers can address these limitations
- Examine how linker design, payload permeability, and medicinal chemistry have been used to fine-tune bystander killing, highlighting lessons from both efficacy gains and toxicity liabilities
- Debate how antibody engineering, immune-mediated mechanisms of action, and novel ADC platforms can unlock greater value from proven payload classes without requiring entirely new warheads



Vicky Appleman
Director, Oncology Drug Discovery
Takeda



Seah Lim
Chief Executive Officer
Medicovestor



Andrew Phillips
Senior Director
AbbVie



Vicky Appleman
Director, Oncology Drug Discovery
Takeda

4.15 Applying a Decade of Topoisomerase ADC Experience to Build the Next Generation of Payloads

- Distill the most important translational and clinical lessons from the widespread adoption of topoisomerase I payloads across multiple tumor settings
- Analyze which resistance mechanisms could have been anticipated and which only emerged through large-scale clinical use, informing more effective development strategies moving forward
- Translate real-world experience into actionable guidance for designing next-generation topo payloads and identifying orthogonal mechanisms capable of addressing resistant patient populations

4.45 Chair's Closing Remarks

5.00 End of Day One

Very high quality talks and open discussion

Scientific Business Development Manager,
Sygnature Discovery

Conference Day Two

Friday, November 6, 2026



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Check In, Coffee & Light Breakfast

8.55 Chair's Opening Remarks

Converging to Define The Future Payload Landscape With New Biology, Expanded Therapeutic Potential & Platform Strategy

9.00 Redefining ADC Payload Design Through Targeted Biology to Expand the Therapeutic Window

- Demonstrate how a non-cytotoxic, mechanism-selective payload approach can address key limitations of traditional cytotoxic ADCs by improving tolerability while maintaining therapeutic activity
- Explore the rationale for targeting TGF- β biology to overcome immunosuppression, resistance mechanisms, and fibrotic disease progression across a range of disease settings
- Highlight opportunities to expand ADC applications beyond conventional oncology paradigms by leveraging targeted biological modulation to improve therapeutic index, unlock novel indications, and create differentiated treatment strategies



Dori Thomas-Karyat
Chief Executive Officer
Synthis Therapeutics

9.30 Panel Discussion: How Does Biology and Resistance Shape The Future Payload Landscape

- Will the future of ADC therapy be driven by a standardized sequence of dominant payload classes, or will tumor-specific biology determine payload choice from the outset?
- To what extent is resistance increasingly driven by payload mechanism rather than target biology, and does this undermine traditional linear sequencing models?
- How does tumor heterogeneity challenge the feasibility of a single, universal payload roadmap across indications?
- What does long-term success look like for next-generation payload strategies in terms of portfolio design, partnering models, and defining clinical value beyond potency?
- What are the implications for pipeline strategy, portfolio design, and payload partnering models?



Kashif Khan
Director, Medicinal
Chemistry & Oncology
AstraZeneca



Prajna Behera
Senior Principal Scientist,
Oncology Innovation
GSK



Alyson Smith
Executive Director,
Biology
Callio
Therapeutics



Kakajan Komurov
Chief Scientific and
Technology Officer
Corellia AI



10.15 Morning Break & Networking

Reprogramming Resistance Through Next-Generation Multi-Payload ADC Strategies

11.15 Reprogramming ADC Resistance Through Mechanistically Matched Payload Combinations

- Analyze ADC resistance mechanisms in topoisomerase and tubulin payloads, including drug efflux pumps and tumor bypass pathways, and distinguish where evidence remains strong versus where it is still incomplete
- Explore approaches to overcoming resistance through rational payload selection, including combining topoisomerase inhibitors with PARP or ATR inhibitors and using translation inhibition strategies to prevent efflux pump expression and resensitize tumors
- Define key requirements for effective dual payload ADC design, including matched payload potency, coordinated intracellular release timing, and engineering strategies that ensure both payloads reach and act in tumor cells simultaneously



Tara Arvedson
Chief Scientific Officer
Hexagon Bio



+1 617 455 4188

@ adc@hansonwade.com

www.adc-payload.com

Antibody Drug Conjugates

World ADC Event Series



Conference Day Two

Friday, November 6, 2026



Wanping Geng
Vice President
CanWell Pharma

11.45 A Systematic Framework for StarLinker Dual-Payload ADC Optimization: Moving Beyond 'Copy-and-Paste' Design

- Mechanism-Driven Optimization: Moving past rigid "me-too" platforms to systematically tune payload selection, potency, ratios, and DAR to maximize initial efficacy while mitigating overlapping toxicities
- An Expanding Modular Library: Translating proven trends across multiple ongoing target programs into a scalable, target-specific linker-payload matching platform
- Robust In Vivo Validation: Utilizing a well-characterized Ab to rigorously validate the engineering blueprint and overcome TOP1i class resistance
- Immune-Stimulating Integration: Expanding the platform to integrate immune-stimulating conjugates, unlocking a dual-attack mechanism for difficult-to-treat cancers



12.15 Lunch & Networking Break



Paul Song
Chief Scientific Officer
Genequantum
Healthcare

1.15 Unlocking Multi-Payload ADC Design Through High-Throughput Screening & Integrated Platform Development

- Enabling rapid synthesis and screening of diverse dual-payload ADCs using a fully integrated discovery platform
- Identifying novel payload combinations and resistance-relevant hits through large-scale screening in PDX models
- Revealing disease-dependent variability in payload efficacy to guide smarter, data-driven ADC design



1.45 Curated Matchmaking Roundtables: Solving ADC Payload Challenges

This interactive networking session is designed to move beyond traditional open networking by bringing together participants in small, pre-curated roundtables aligned to shared scientific and strategic challenges. Attendees will have freedom to rotate between focused discussions, enabling deeper exchange on key ADC payload issues and creating targeted opportunities to identify collaborators.

- Join carefully matched discussion groups built around shared scientific challenges, development needs, and partnership opportunities rather than random networking
- Exchange practical insights on critical payload topics including overcoming resistance, translating novel payloads, balancing potency and safety, and identifying the right development partners
- Rotate through challenge-focused discussions to compare strategies, uncover new solutions, and identify the most valuable follow-up conversations and collaborations



2.30 Afternoon Break & Further Networking

Conference Day Two

Friday, November 6, 2026



WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Diversifying ADC Payload Mechanisms Through Emerging Biological Approaches



Satyajit Mitra
Executive Director,
Head of Oncology
Akari Therapeutics

3.00 Benefits of Alternative ADC Mechanisms Beyond Cytotoxicity: Rationale for RNA Splicing Payloads That Induce Cell Death & Activate Anti-Tumor Immunity

- The Hypothesis: Examine the scientific rationale for leveraging RNA splicing modulation as a novel ADC payload mechanism that delivers a dual anti-tumor effect through direct cytotoxicity and immune system activation, offering differentiation beyond traditional microtubule inhibitors and DNA-damaging payloads
- The Journey: Engineering desired features such as MDR resistance and development of payload-specific conjugation strategies. Why cleavable vs non-cleavable strategies need to be revisited for each novel payload.
- The Pay-off: Early translational and preclinical data supporting anti-tumor cytotoxic activity, including evidence of immune activation and activity across oncogenic driver-driven cancer models
- Future Directions: How next-generation RNA splicing modulator payloads could expand the ADC therapeutic landscape through differentiated mechanisms of cell death, potential combination synergy with immunotherapies, and opportunities for broader antigen targeting strategies



James Prudent
Chief Executive Officer
Centrose LLC

3.30 A Next-Gen ADC Platform Exploiting Cell Surface Proximity

- The expression and distance between cell surface proteins that can be exploited in the ADC field
- Technology used to measure the distance between proteins expressed on cell surfaces
- Potent yet safe ADCs that do not require internalization nor Antibody-Drug separation that have been developed
- Overcoming resistance using a non-internalizing payload



Koichi Ito
Senior Director, Biology
Prelude Therapeutics

4.00 Redefining ADC Payload Design Through Degradable Conjugates & Evolving Medicinal Chemistry Principles

- Gain a clear understanding of how degradable antibody conjugates introduce new opportunities and risks compared to classical cytotoxic payload approaches
- Learn how medicinal chemistry strategies are evolving beyond potency to optimize broader property space including DMPK and developability considerations
- Explore practical frameworks for evaluating emerging payload modalities and determining when ADC delivery adds value over small molecule approaches

4.30 Chair's Closing Remarks

4.45 End of Conference

■ A focused 3-day event providing insightful ideas, data, and discussion on the current landscape of ADC payloads, ways to improve upon existing molecules, and promoting research into new payload classes ■

Business Development Manager, **Klus Pharma**

Meet Our 2026 Partners

3rd Annual
adc
Payload Summit
November 4-6 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Expertise Partner: WuXi XDC

WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.

www.wuxixdc.com

Meet C-Level Decision Makers From:



Great mix of talks and time to discuss with colleagues.
Nice diversity in talk content

InhibRx

There were many subject matter experts present and
creative payload ideas presented

ALX Oncology

Get Involved



Nicholas Ramovic
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Partner With Us

adc
3rd Annual
Payload Summit
November 4-6 2026
Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Exclusive Opportunity to Build Strategic Partnerships & Position Your Brand at the Forefront of ADC Payload Innovation



The Only Industry Forum Dedicated to Payload Design & Innovation

Designed specifically for payload discovery, chemistry, biology, translational and ADC R&D leaders, the ADC Payload Summit brings together the innovators advancing both established and next-generation warheads. Engage a highly targeted audience focused on overcoming resistance, expanding therapeutic windows, unlocking novel mechanisms of action, and accelerating the development of differentiated ADC payload platforms.



Direct Access to the Companies Defining the Next Era of ADC Efficacy



With record-breaking investment across the sector, including major acquisitions by Novartis, Gilead and Johnson & Johnson, the race to develop differentiated payload technologies has never been stronger. Meet the scientists, executives, and decision-makers actively seeking new technologies, capabilities, and strategic partners to advance ADC pipelines and bring next-generation therapies to patients.




Showcase Your Solutions Against the ADC Industry's Biggest Challenges

Position your expertise in front of leaders tackling critical payload development hurdles, including resistance, potency-toxicity optimization, translational predictability, dual-payload engineering, linker-payload design, and novel mechanisms of action. Demonstrate how your technologies can accelerate development, reduce risk, and help ADC innovators deliver more effective and differentiated therapeutics.

Seniority of Attendees



Type of Companies Attending



*Statistics taken from the 2nd ADC Payload Summit 2025

Get Involved



Nicholas Ramovic
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

-  www.adc-payload.com/register/
-  Tel: +1 617 455 4188
-  Email: info@hansonwade.com



Stay Ahead of the Next Wave of ADC Payload Innovation, exploring novel cytotoxics, degrader conjugates, emerging mechanisms of action and dual-payload strategies that are reshaping the future of ADC development and attracting major industry investment



Maximize the Therapeutic Potential of Existing and Next-Generation Payloads, gaining practical insights into overcoming resistance, expanding the therapeutic window, balancing potency with safety, and leveraging smarter linker, antibody, and payload design decisions to drive superior clinical outcomes



Build Strategic Connections to Accelerate ADC Development, participating in brand new curated matchmaking roundtables and focused scientific discussions with leading payload, chemistry, biology, translational, and R&D experts to exchange solutions, identify collaborators, and advance the most promising payload platforms toward clinical success

Drug Developers	Register & Pay By Friday, August 7 & Save up to \$900	On the Door Price
Conference + Workshop Day	\$3,397	\$4,297
Conference Only	\$2,599	\$3,099
Academic & Research Institutes**	Register & Pay By Friday, August 7 & Save up to \$900	On the Door Price
Conference + Workshop Day	\$2,797	\$3,697
Conference Only	\$2,199	\$2,699
Solution & Service Providers	Register & Pay By Friday, August 7 & Save up to \$1000	On the Door Price
Conference + Workshop Day	\$4,297	\$5,297
Conference Only	\$3,299	\$3,799

*To qualify for the drug developer rate your company must have a public drug pipeline and not provide fee-based services. Please visit the website for full pricing options or email info@hansonwade.com

**To qualify for academic and research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com

Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

Venue

Hotel Commonwealth

500 Commonwealth Avenue, Boston, Massachusetts, USA, 02215

www.hotelcommonwealth.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade Conferences Limited is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Conferences Limited, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom